Clinical Trials List
2020-06-01 - 2029-12-31
Phase II
Recruiting7
ICD-10C76.0
Malignant neoplasm of head, face and neck
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9195.0
Malignant neoplasm of other and ill-defined sites of head, face and neck
-
Trial Applicant
Merck Sharp & Dohme (I.A.) LLC
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/04/01
Investigators and Locations
Co-Principal Investigator
- Mu-Hsin Chang Division of Hematology & Oncology
- Tien-Hua Chen Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- HUAI-CHENG HUANG Division of Hematology & Oncology
- YA-FANG CHEN Division of Radiology
- 黃彥霖 Division of Others
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Chia-Jui Yen Division of General Internal Medicine
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Tzu-Chen Yen Division of Nuclear Medicine
- Chi-Ting Liau Division of Hematology & Oncology
- Chia-Hsun Hsieh Division of Hematology & Oncology
- Shu-Hang Ag Division of Radiology
- Li-Yu Lee Division of Others -
- 廖俊達 Division of Otolaryngology
- Cheng-Lung Hsu Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Tai-Jan Chiu Division of Hematology & Oncology
- 陳彥豪 Division of Hematology & Oncology
- 賴香蘭 Division of Hematology & Oncology
- 黃泰霖 Division of Hematology & Oncology
- Yu-Li Su Division of Hematology & Oncology
- 林偉哲 Division of Radiology
- 黃詩喻 Division of Hematology & Oncology
- 李易濰 Division of Radiology
- 吳佳哲 Division of Hematology & Oncology
- 劉建廷 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 鄭皓升 Division of Radiation Therapy
- ZHENG-WEI ZHOU Division of Hematology & Oncology
- 謝合原 Division of Radiation Therapy
- CHENG-HSIEN LIN Division of Hematology & Oncology
- 陳建志 Division of Radiation Therapy
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Yu-Min Liao Division of Hematology & Oncology
- Ching Yun Hsieh Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
約18人 participants
-
Global
約400人 participants
